Improving olaparib exposure to optimize adverse effects management

Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre, Antonin Schmitt

Open source

DOI: 10.1177/17588359241248328
Published: 2024-01
Container: Therapeutic Advances in Medical Oncology
Publisher: SAGE Publications
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/17588359241248328,
  title = {Improving olaparib exposure to optimize adverse effects management},
  author = {Marylise Sterlé and Alicja Puszkiel and Chloé Burlot and Eva Pereira and Audrey Bellesoeur and Sixtine De Percin and Guillaume Beinse and Jean-David Fumet and Laure Favier and Julie Niogret and Benoit Blanchet and Bernard Royer and Leïla Bengrine-Lefevre and Antonin Schmitt},
  year = {2024},
  journal = {Therapeutic Advances in Medical Oncology},
  doi = {10.1177/17588359241248328},
  url = {https://doi.org/10.1177/17588359241248328}
}

RIS

TY  - JOUR
TI  - Improving olaparib exposure to optimize adverse effects management
AU  - Marylise Sterlé
AU  - Alicja Puszkiel
AU  - Chloé Burlot
AU  - Eva Pereira
AU  - Audrey Bellesoeur
AU  - Sixtine De Percin
AU  - Guillaume Beinse
AU  - Jean-David Fumet
AU  - Laure Favier
AU  - Julie Niogret
AU  - Benoit Blanchet
AU  - Bernard Royer
AU  - Leïla Bengrine-Lefevre
AU  - Antonin Schmitt
PY  - 2024
JO  - Therapeutic Advances in Medical Oncology
DO  - 10.1177/17588359241248328
UR  - https://doi.org/10.1177/17588359241248328
ER  -

APA

Sterlé, M., Puszkiel, A., Burlot, C., Pereira, E., Bellesoeur, A., Percin, S. D., Beinse, G., Fumet, J., Favier, L., Niogret, J., Blanchet, B., Royer, B., Bengrine-Lefevre, L., & Schmitt, A. (2024). Improving olaparib exposure to optimize adverse effects management. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/17588359241248328

Source records

crossref · retrieved 2026-09-27T02:34:03.311Z